Medivir AB Release: New Data From Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients Will be Presented at EASL 23-28 April in Amsterdam
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients. These primary efficacy and safety results from two global phase III studies demonstrate that use of the investigational protease inhibitor simeprevir led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naïve genotype 1 chronic hepatitis C adult patients with compensated liver disease, when administered once daily with pegylated interferon and ribavirin. In both studies, 50 percent of patients receiving pegylated interferon and ribavirin alone achieved SVR12.
Help employers find you! Check out all the jobs and post your resume.
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients. These primary efficacy and safety results from two global phase III studies demonstrate that use of the investigational protease inhibitor simeprevir led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naïve genotype 1 chronic hepatitis C adult patients with compensated liver disease, when administered once daily with pegylated interferon and ribavirin. In both studies, 50 percent of patients receiving pegylated interferon and ribavirin alone achieved SVR12.
Help employers find you! Check out all the jobs and post your resume.